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between 1960 and 2015 in English language. Phase II, III or IV clinical trials with at-
least one study arm assessing a treatment of interest were included. PRO studies 
(not limited to RCTs) reporting quality-of-life (QoL) data for these compounds were 
included. Additionally, information was extracted from product package inserts 
of molecules within FDA indication. Archives of 27 HTA bodies were searched for 
qualifying HTAs of these compounds as well. Patient characteristics, primary and 
secondary endpoints, safety, QoL and reimbursement decisions were extracted 
exhaustively from qualifying studies and HTAs. Results: So far, data are avail-
able for 15 cancers, including 90 agents in 487 studies. The interactive, user-friendly 
MS-Excel® based tool can be used to study any selected cancer, including conduct 
meta-analyses, generate summaries and reports of clinical, PRO and HTA data. The 
registry provides functionality for a user to make desired assessments via multiple 
variables such as line of treatment, tumor-stage, molecule, grade of adverse events 
and so on. ConClusions: OncoLitBank provides up-to-date data and a robust 
platform that can be easily used for systematic reviews, to conduct direct and indi-
rect comparisons through meta-analyses, to inform economic models, perform 
landscape analyses, produce value dossiers,and to create target product profiles and 
value development plans. Expansion of searches to other literature databases and 
trial registries and inclusion of economic and epidemiology studies are underway.
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objeCtives: To generate costs and costing algorithms for treatment and supportive 
drugs in oncology using provincial (Ontario) administrative databases. Methods: 
A cohort of women diagnosed with breast cancer (BC) (ICD-9 174.x) was identi-
fied from the Ontario Cancer Registry (2007-2010). Firstly, the Ontario Drug Benefit 
Formulary (ODBF), New Drug Funding Program (NDFP) and Activity Level Reporting 
(ALR) databases was used in which BC-specific treatments (chemotherapies and 
hormonal therapies) and supportive drugs were identified. Secondly, unit costs were 
applied to calculate the overall and per drug costs in each database. Lastly, costing 
algorithms were generated to conduct the costing analyses. Results: We identified 
30,338 women diagnosed with BC. All chemotherapies and hormonal therapies were 
named as well as anti-nausea, pain (opioid and non-opioid), anti-infectives, and 
blood products for supportive drugs. Outputs include number of patient cases with 
at least one treatment or supportive drug being utilized and total costs. Preliminary 
results for the 20,076 BC cases prescribed a drug in ODBF totalled $69.5 million in 
which $37.5 million was treatment-specific. ConClusions: We have generated 
preliminary ODBF costs for oncology drugs in BC and costs for the NDFP and ALR 
databases will be determined next. These costing algorithms will allow for the calcu-
lation of oncology treatment and supportive drug costs in different cancer cohorts.
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objeCtives: Repositories of “big data” have the potential to play a pivotal role in 
advancing Alzheimer’s disease (AD) research. Globally, AD-specific data are being 
generated and aggregated into research databases. An environmental scan was 
conducted to identify worldwide AD-specific databases and types of data being 
aggregated and used for AD research. Methods: A Google search was conducted 
monthly starting in September 2014 to present. For each database, its URL, geo-
graphic location, funding source, and type of data collected and/or stored were 
identified. A categorization scheme was established to classify types of data. Three 
reviewers independently categorized the data as: 1 = claims, 2 = laboratory, 3 = 
genetic, 4 = imaging, 5 = patient/caregiver-reported questionnaires, 6a= longitudi-
nal study, 6b = patient registry, 7 = clinical data, 8 = electronic medical records, 9 = 
neuropathology, and O = other. A fourth reviewer resolved discrepancies. Results: 
A total of 53 AD databases were identified, both within (28/53) and outside the U.S. 
(21/53). Sources from outside the U.S. include United Kingdom, Australia, Belgium, 
France, etc. Four databases represent U.S. and non-U.S. collaborations. The National 
Institutes of Health is the most common funding source (14/53). Clinical data were 
found to be the most common (30/53); whereas, databases containing AD-specific 
claims data appear to be lacking. Additional gaps include a comprehensive database 
linking claims data with patient-level data from AD longitudinal studies, patient 
registries, electronic medical records, or genetic data. Patient registry databases 
lack pre-diagnosis and early-life data, as they enroll patients upon diagnosis with 
AD or mild cognitive impairment. ConClusions: Various types of data are being 
aggregated into numerous AD-specific research databases worldwide. However, gaps 
exist that may limit the utility of these databases in making advances in the AD 
research. Efforts are needed to explore opportunities to merge and expand these 
databases to fill these critical gaps.
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objeCtives: Social Listening through digital media may offer a unique opportunity 
to enhance traditional pharmacovigilance strategies. The objective of this pilot study 
was to evaluate the breadth of pharmaceutical products and vaccines most com-
monly discussed on Facebook and Twitter and how these data may inform future 
research in this area. Methods: Publically available Facebook and Twitter posts 
of lifetime direct medical costs for first-ever stroke patients can have implication 
in public health policy planning and clinical decision making.
ReseaRCh on MethoDs – Databases & Management Methods
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objeCtives: Several indices have been developed to adjust for the effects of comor-
bid conditions in observational studies. This study aimed to determine which among 
selected indices provides the optimal covariate in cost analyses assessing resource 
utilisation between different treatment strategies using a UK primary care data-
base. Methods: A retrospective analysis of UK patients continuously registered 
with a single general medical practice between 01/01/2007 and 01/01/2011 was con-
ducted using the Clinical Practice Research Datalink GOLD dataset (CPRD). Three 
comorbidity indices were compared: the Charlson Comorbidity Index, original ver-
sion (CCI) and 2008 adaptation (CCI-2008), and the Quality Outcomes Framework 
(QOF). In addition, we considered a bespoke index based on an unweighted count 
of diseases included in the Charlson indices. Two resource use outcomes were 
analysed: 1) the monthly frequency of primary care consultations; and 2) annual 
count of biological tests reported over the calendar year 2010. The sensitivity of 
the comorbidity indices were evaluated for three different look-back periods: 12, 
24 and 36 months. For each outcome, we fitted mixed linear regression models 
with comorbidity index, age and gender as fixed-effects factors and covariates, and 
general practice as random intercept. Comorbidity indices were ranked according to 
goodness-of-fit, assessed by R2 and Akaike’s Information Criterion (AIC). Results: 
4,694,610 patients were included in the analysis. The CCI-2008 ranked highest based 
on correlation with both consultations (R2= 0.11) and tests (R2= 0.16), followed by the 
CCI (R2= 0.09 and R2= 0.14 for consultations and tests respectively) and then the QOF 
measure (R2= 0.08 and R2= 0.11 respectively). Unweighted counts of comorbidities 
showed similar AIC and R2 as their weighted counterparts. The same ranking was 
observed over the three co-morbidity look-back periods. ConClusions: The CCI-
2008 performed better than CCI and QOF to predict units of primary care resource 
utilisation observed in UK general practice. Further analyses will determine whether 
these findings are confirmed when predicting health resource use costs and if repro-
ducible in other health systems with alternative data collection methods such as 
claims databases.
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objeCtives: Multiple sclerosis (MS) is a degenerative neurologic disease that seri-
ously affects patients’ quality of life. Fingolimod is a sphingosine-1-phosphate 
modulator that traps lymphocytes in lymph nodes with neuroprotective effects. 
Our objective was to review the available evidence regarding its efficacy in disease 
progressions, relapse rate and brain atrophy and link it to possible phamaeconomic 
effects. Methods: A systematic review of literature was performed in MEDLINE 
and Scopus. We included primary studies comparing fingolimod to placebo or other 
drugs regarding its efficacy in disease progression, relapse rate and brain atrophy. 
Retrospective designs and studies focusing on specific populations were excluded. 
Data regarding the outcomes of interest were extracted and processed with Review 
Manager 5.3. Results were presented with forest plots, and heterogeneity analysis 
was performed. We performed a literature review to assess the possible effect of 
these clinical outcomes in terms of costs and quality adjusted life years (QALY) in 
the Colombian context. Results: From the 1,344 references originally identified, 
only 3 had useful information. Two were placebo-controlled and the other one used 
interferon ß1a (IFß1a) as control. Information was available for 1.25 mg and 0.5 mg 
fingolimod dosing. Statistically significant differences in favor of fingolimod were 
found in annualized relapse rate, brain volume change, percentage of relapse and 
disease progression-free patients compared to placebo or IFß1a. Results EDSS and 
MSFC scales change were favorable to fingolimod but not statistically significant. 
Using data from various sources, we estimated that Colombian patients treated 
with fingolimod for 5 years might avoid a loss of 0.145 QALY and $ 5,029 of direct 
and indirect costs. ConClusions: Fingolimod is superior to placebo and IFß1a in 
disease progression, relapse rate and brain atrophy. More studies are warranted, 
especially comparing fingolimod to other drugs. The estimated pharmacoeconomic 
effects are promising but must be interpreted with caution.
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objeCtives: We created OncoLitBank, to capture data from clinical trials, patient 
reported outcomes (PRO) studies,and Health Technology Assessments (HTAs) in 
oncology. The registry is aimed to provide efficient access, and comprehensive anal-
yses of data for the evolving landscape of chemotherapy agents. Methods: A sys-
tematic literature search was conducted on PubMed for chemotherapy compounds 
by cancer indications that were either FDA-approved or National Comprehensive 
Cancer Network (NCCN) recommended. The search was limited to studies published 
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objeCtives: Electronic medical records (EMR) are increasingly utilized in clini-
cal practice and research, allowing for more efficient availability of rich patient 
records. However, most use of EMR is limited to coded, structured, and adminis-
trative data, while the vast majority of patient information (e.g. disease subtype, 
severity, medical device usage, etc.) is tied up in narrative clinical notes. The chal-
lenge remains in accessing the information in these patient notes. Historically 
this has been done via timely and costly manual chart review, but as the amount 
of EHR data increases exponentially, manual chart review becomes impractical 
and impossible. Advancements in Natural Language Processing (NLP) have dem-
onstrated promising results in combining the capture of additional clinical note 
information with the efficiency of modern informatics. The objective of this study 
is to demonstrate the relevancy and utility of NLP to extract health data from 
EMR in real-world observational studies. Methods: We conducted a systematic 
review and meta analysis of performance metrics for five (5) NLP-driven projects 
involving oncology, inflammation and medical devices ,which had similar proto-
cols and objectives. We assessed and validated the accuracy of NLP algorithms, 
as well as heterogeneity of accuracy between studies using random effects meta-
analysis (represented by I2 value). Results: A total of 382,523 patients were 
identified using NLP among the 5 studies. Accuracy among the studies ranged 
from 95.2% to 100% (95% CI: 95.1%, 100%), with an I2 value of 95.9% (95% CI: 92.9%, 
97.7%). ConClusions: NLP provide a unique opportunity to extract meaningful 
information from patient-level narrative clinical notes in EMR data sources with 
high degree of accuracy. This provides additional rich sources of data from narra-
tive clinical notes, that are otherwise not easily available, to support epidemiology 
and other real-world observational studies.
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objeCtives: Regarding compliance analysis numerous ratios can be found in 
international scientific literature with simpler or more complex methodology. In 
our analysis we tend to reveal, that choosing an adequate ratio is not sufficient 
itself, it is essential to know the difficulties and pitfalls of the data management 
and methodology to the objective assessment of the chosen ratio. The chief aim 
of our study to demonstrate factors in course of practical examples, which may 
substantially influence the results and the right conclusions, if these factors are 
modified. Methods: The analysis is based on prescription refilling’s data of 
database of the Hungarian Health Fund in the field of the following indications: 
diabetes, COPD, oncology. From the ratios available in scientific literature, the PDC 
(Proportion of Days Covered) was chosen. The following aspects were considered 
as influencing factors: patient inclusion criteria (index date, time frame, criteria 
of refillings); DDD (WHO, SPC or real-world dosage to DOT); Gap (period without 
medication supply). A basic setting was established to calculate PDC ratio, then 
after changing each above specified parameters one by one (ceteris paribus), the 
ratio was recalculated. Results: The PDC ratio shows huge variability recalcu-
lated by the different values of each parameters. Even more than 20% difference 
can be observed after modifying the gap (strict 1-day or permissive 30-day), or 
applying the SPC dosage instead of WHO DDD. In course of modifying the patient 
inclusion criteria both patient numbers and the ratio also show significant differ-
ences. ConClusions: Based on the results it may be concluded, that no general 
best practice can be observed, all settings have both advantages and limitations. 
It may be worth choosing the key parameters considering the specialties of each 
indications in order to draw conclusions as correct as possible with the focus of 
the original aim of the study.
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objeCtives: Generic comorbidity measures developed to predict mortality and/
or healthcare costs are often used as adjustment covariates in observational stud-
ies comparing health expenditures between different therapeutic strategies. The 
objective of this review is to identify available measures, and assess their perfor-
mance for prediction of economic outcomes using large longitudinal patient data-
bases. Methods: We conducted a comprehensive literature search in MEDLINE, 
until April 2015. All methodological papers describing a new comorbidity measure 
or assessing their ability to predict economic outcomes using administrative data or 
electronic medical records were selected. We search for additional studies through 
references lists of selected articles. We extracted information on the conditions 
for using each index and predictive performance. Results: 323 abstracts were 
identified during the search in MEDLINE and 25 full papers were reviewed. Eleven 
comorbidity measures and seven comparative studies were found. Four comorbid-
ity measures were single cumulative weighted scores: two were diagnosis-based 
indexes developed using large administrative health databases and two others were 
medication-based indexes developed using pharmacy data. Two comorbidity meas-
urement systems consisted in classifying patients in mutually exclusive groups 
defined based on diagnosis and clinical or economical characteristics. Others were 
simple counts of diseases. All measures were based on a list of diseases pre-selected 
by clinicians, except for the Ambulatory Clinical Groups System (ACG). Five meas-
ures were adapted for use with ICD-9-CM and ICD-10 classifications. Hierarchical 
Cost Groups (HCC-CMS) and Quality and Outcome Framework (QOF) showed the 
highest predictive ability in three comparative studies. ACG was the best predictor 
in one study and the second one in three other analyses. ConClusions: HCC-
CMS and QOF were reported to have the best predictive performance. However 
most comparative studies included a limited number of comorbidity measures. 
containing at least one product and one adverse event keyword were collected, de-
identified, and standardized using a vernacular to MedDRA dictionary. Posts were 
classified as resembling an adverse event report (Proto-AEs) or simply discussing 
a product (Mention). Results: There were a total of 1,410,819 posts categorized 
as Proto-AEs, 265,838 (19%) from Facebook and 1,144,981 (81%) from Twitter. The 
top 10 products accounted for 940,666 (67%) of the total Proto-AEs in Facebook and 
Twitter combined. The top 25 accounted for 1,180,040 (84%), the top 50 for 1,285,836 
(91%), and the top 100 for 1,245,010 (95%) of the total Proto-AEs. The top 10 products 
(diphenhydramine, flu vaccine, dextroamphetamine, codeine, morphine, ibuprofen, 
alprazolam, acetaminophen, oxycodone, and zolpidem) were comprised of six con-
trolled substances, three over-the-counter (OTC) products, and one class of vaccine. 
Of the top 50 products, controlled substances accounted for 32%, OTC products for 
24%, and vaccines for 10%. ConClusions: Review of publically available data over 
the past two years from two popular social media sites, Facebook and Twitter, offers 
a high number of potential adverse events (Proto-AEs) for further evaluation. Social 
listening may be potentially valuable as a supplement to traditional pharmacovigi-
lance practices, particularly for controlled substances, over-the-counter products, 
and vaccines. These initial findings warrant more research and a closer inspection 
as to the nature of these posts.
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objeCtives: There are a number of search filters designed to identify studies 
with particular study designs in electronic databases. This study compared three 
filters for identifying randomised controlled trials (RCTs). Methods: Searches 
were conducted on 15thJune 2015 in the Ovid MEDLINE and MEDLINE In-process 
databases using The Cochrane Highly Sensitive Search Strategy for Identifying 
Randomized Trials in MEDLINE, the SIGN Randomised Controlled Trials MEDLINE 
filter and the BMJ MEDLINE Randomised Controlled Trial Strategy. Differences were 
explored by reviewing samples of records uniquely identified by each filter. For 
comparison, a sample of articles returned by all three filters was also reviewed. 
To estimate the sensitivity of each filter, the detection of 39 publications of RCTs 
included in a randomly-selected Cochrane Collaboration systematic literature 
review (SLR) was tested. Results: 476,551 records were identified by all three 
filters. From a sample of 384 records, 230 were RCTs and 18 were SLRs, meta-
analyses or pooled analyses of RCTs. 1,000,716 records were uniquely identified 
by the Cochrane filter; of 400 records sampled , 0 were RCTs and 3 were SLRs 
or meta-analyses of RCTs. 500,127 articles were uniquely identified by the SIGN 
filter; of 386 records sampled, 8 were RCTs and 1 was a meta-analysis of RCTs. 
84,938 records were uniquely identified by the BMJ filter; of 400 records sampled, 
6 were RCTs and 5 were SLRs or meta-analyses of RCTs. 39/39, 38/39 and 37/39 of 
the Cochrane review publications were identified by the Cochrane, SIGN and BMJ 
filters, respectively. The publication missed by the SIGN filter was not the same as 
the 2 missed by the BMJ filter. ConClusions: All filters failed to identify at least 
some RCTs, SLRs or meta-analyses of RCTs. Differences between filters, including 
the publications uniquely identified by each, should be considered when selecting 
filters for use in literature reviews.
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objeCtives: OncoLitBank is a registry of published oncology trials and Health 
Technology Assessments aimed to help provide a platform for secondary data 
analytics in the field of oncology. To demonstrate the utility and functionality of 
OncoLitBank, we conducted a basic indirect treatment comparison (ITC) between 
gemcitabine/nab-paclitaxel (GemNpac) and gemcitabine/capecitabine(GemCap) 
combinations which were each tested against gemcitabine but not against 
each other for treatment of metastatic pancreatic cancer. Methods: Using 
OncoLitBank, data for metastatic pancreatic cancer were filtered for treatment-
comparator arms of interest by using built-in interactive features. Two phase III 
randomized controlled trials (RCTs) comparing GemCap vs Gem, while 1 RCT 
comparing GemNpac vs Gem were included for the ITC. Data on overall response 
rate (ORR), 1-year survival, overall survival (OS), progression-free survival (PFS), 
and grade 3-4 adverse events (AEs) were pooled for the 2 RCTs comparing GemCap 
vs Gem using RevMan 5.0. Pooled risk ratios (RRs) and mean differences (MD) 
for the 2 studies were derived for dichotomous and continuous outcome vari-
ables respectively and compared to the single RCT that evaluated GemNpac vs 
Gem to derive the ITC RRs and MDs using the Canadian Agency for Drugs and 
Technologies in Health (CADTH) ITC application which employs Bucher et al. 
(1997) method. Results: The use of OncoLitBank was successful and eliminated 
the need to conduct a new systematic review to perform the ITC leading to a 
quick turn-around of tasks at hand. Results demonstrated that GemNpac was 
not superior to GemCap in ORR, 1-year survival, OS, PFS and grade 3-4 AEs, as 
no significant differences was detected. ConClusions: OncoLitBank provides 
users with a robust data platform that can be easily used for systematic reviews, 
conduct meta-analyses through direct orindirect comparisons, inform economic 
models, landscape analyses, value dossiers, create target product profiles and 
value development plans.
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